Two of Europe’s biggest drugmakers warned on Tuesday there would be no let up in pressure on U.S. medicine prices after last week’s presidential election win for Republican Donald Trump, which sent pharmaceutical and biotech shares soaring.
Mergers and acquisitions (M&A) in the sector, meanwhile, could get a big boost if Trump pushes through plans for a U.S. “tax holiday” on repatriated overseas profits, executives said.
Both France’s Sanofi and Britain’s GlaxoSmithKline have recent direct experience of U.S. pricing pressure, with healthcare providers forcing big discounts for their top-selling diabetes and respiratory medicines.
In the run-up to the U.S. election, investors had focused on the threat of price controls posed by Democrat Hillary Clinton, yet Trump also advocated a new role for government agencies in negotiating down drug costs.
“I don’t think the pricing debate is over,” Sanofi Chief Executive Olivier Brandicourt told an industry conference.
Drugmakers are already having to work much harder to justify U.S. prices due to the rising power of U.S. pharmacy benefit managers (PBMs), which administer drug benefits and negotiate rebates for employers and health plans.
The buying power of these middlemen has been brought to bear particularly in areas of medicine where there are several similar treatments to choose from, such as insulin injections and inhalers for asthma and chronic lung disease.
The trend toward big buyers squeezing prices is only going to accelerate as the U.S. healthcare system struggles to find the resources to pay for new medical interventions, GSK CEO Andrew Witty said.
“It doesn’t really matter too much who won the U.S. election because the direction of travel of the U.S. marketplace, owned not by one stakeholder in the White House but by multiple stakeholders in public and private decision-making environments, is already set,” he told the Financial Times meeting.
Manufacturers contend that the discounts extracted by PBMs are not always passed on to patients.
“We are making significant concessions but patients are paying more,” said Brandicourt, who believes legislation may eventually be needed to ensure patients gain from the discounts.
Another key question for investors is the potential for a further wave of deal-making in the healthcare sector, given impetus by Trump’s plan to work with Congress to allow U.S. firms to pay a lower tax rate when bringing back overseas cash.
That would add tens of billions of dollars in firepower for pharma and biotech acquisitions, with deal-hungry Pfizer alone having more than $80 billion it wants to repatriate.
“I think there is likely to be quite a lot of M&A next year,” said GSK’s head of strategy David Redfern. “The only thing unclear is how big it gets.”
By Ben Hirschler
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.